What types of bleeding have been linked to taking the dangerous drug Xarelto?

Since 2011, Xarelto has been used as a blood thinner to prevent blood cots and strokes in patients. The U.S. Food and Drug Administration (FDA) approved this medication for use by patients who have undergone hip or knee replacement surgeries, patients with atrial fibrillation, and patients with pulmonary embolism, or deep vein thrombosis. Unfortunately, the use of Xarelto has also been linked to serious injuries and even death.

Five Types of Bleeding Linked to the Drug Xarelto

Why is this drug so dangerous? Xarelto does not have an antidote in order to stop any uncontrollable bleeding. This is perhaps the most serious side effect associated with the drug. Studies have shown a link between the taking of Xarelto and the following types of dangerous bleeding:

  1. Spinal bleeding
  2. Rectal bleeding
  3. Intestinal bleeding
  4. Abdominal bleeding
  5. Bleeding in the brain

Perhaps even more frightening is the fact that internal bleeding such as that described above is not always associated with obvious symptoms. Instead, victims may experience blood in their stool, fatigue, pale skin, abdominal swelling, bruising, dizziness, and stroke-like symptoms. Many of these symptoms can mistakenly be attributed to other causes. The internal bleeding caused by Xarelto will continue until the medication is flushed out of the body. This could lead to serious complications and even death. The risks are especially high when the bleeding occurs close to a major bodily organ or pools of blood begin to form inside the body.

It is important to help educate your friends and loved ones about the dangers of this drug. It has been shown to be especially dangerous for pregnant women, people taking platelet inhibitors, people taking NSAIDS or other medications that can impact blood clotting, patients using epidural catheters, and patients with a history of spinal trauma or spinal surgery. We encourage you to help spread the word by sharing a link to this article on Facebook or Twitter.